News for Healthier Living

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment. In one of the largest real-world studies to date examining obesity treatment use and long-term weight changes after GLP-1 discontinuation, researchers at Cleveland Clinic found that many patients successfully stabilized their weight after one year through alternative treatments and therapeutic lifestyle interventions. The findings published in the journal Diabetes, Obesity and Metabolism.

March 12, 2026


March 13 2026

March 12 2026

March 11 2026

March 10 2026

March 9 2026

March 8 2026

March 7 2026

March 6 2026

March 5 2026

March 4 2026

March 3 2026

March 2 2026

March 1 2026

February 28 2026

February 27 2026